BioSpace News Archive

The American Society for Transplantation and Cellular Therapy® (ASTCT®) recognizes the US Food and Drug Administration’s (FDA) recently granted approval for two gene therapies aimed at treating Sickle Cell Disease (SCD).

Mitsubishi Tanabe Pharma Canada a subsidiary of Mitsubishi Tanabe Pharma America, Inc., announced that RADICAVA® Oral Suspension for the treatment of amyotrophic lateral sclerosis, a rapidly progressive, neurodegenerative disease1, is now reimbursed by Veterans Affairs Canada and Indigenous Services Canada via the Non-Insured Health Benefits Program.

Cerno Bioscience, the leading provider of accurate mass spectrometry software solutions, has launched its latest automated system, GC/ID™ Version 5.0, to validate and improve GC/MS Library Search.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. District Court for the District of Delaware has granted summary judgment to Acadia, confirming validity of the NUPLAZID® (pimavanserin) ‘740 composition of matter patent.

The U.S. Food and Drug Administration is providing an update on its efforts to create a unified Human Foods Program and new Office of Regulatory Affairs model, including additional details about the proposed structure, status of activities and timeline for next steps.

Crown Aesthetics, a Crown Laboratories, Inc. company, announced that its groundbreaking clinical study, recently accepted for publication in the Journal of Clinical and Aesthetic Dermatology, has further shed light on the significant role its skin-biome care product line, BIOJUVE™, may have in the advancement of the practice of dermatology.

Inhibitor Therapeutics, Inc. has entered into an exclusive, worldwide licensing agreement with Johns Hopkins University for their U.S Patent 8,980,930 “New Angiogenesis Inhibitors”.

Implement a waste-to-energy strategy to divert from landfills’ waste from several of our laboratory locations by 2025.

Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has achieved gram-scale synthesis with its Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis™ technology.

Y-mAbs Therapeutics, Inc. today announced it will be added to the NASDAQ Biotechnology Index (NASDAQ: NBI), effective prior to the market open on Monday, December 18, 2023.